"At IMBCR, we have boldly set out to reimagine how we approach treatment, management, and drug development strategies for multiple myeloma and other devastating malignancies. We focus on the individual needs of patients, not just treatment, but holistic care. Working alongside industry leaders and other centers of excellence from around the world, we explore available & novel drugs to determine the optimal, unconventional combinations to maximize their benefit. Our mission is to advance the treatment of myeloma by connecting possibility through scientific innovation leading to personalized and continuous optimized patient care."

During the past decade, Institute for Myeloma and Bone Cancer Research conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Institute for Myeloma and Bone Cancer Research" are "Multiple Myeloma" (2 trials). Many other conditions were trialed in "Institute for Myeloma and Bone Cancer Research" in a lesser frequency.

Most popular intervention types in "Institute for Myeloma and Bone Cancer Research" are "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "ATN-224 + bortezomib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute for Myeloma and Bone Cancer Research" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Institute for Myeloma and Bone Cancer Research". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Institute for Myeloma and Bone Cancer Research, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institute for Myeloma and Bone Cancer Research, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".